TCGA-GM-A3XL-01A-11R-A22U-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 70
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.680
- E2F_TARGETS+0.590
- MYC_TARGETS_V1+0.580
- INTERFERON_ALPHA_RESPONSE+0.540
- OXIDATIVE_PHOSPHORYLATION+0.480
- G2M_CHECKPOINT+0.460
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.460
- MTORC1_SIGNALING+0.430
- INTERFERON_GAMMA_RESPONSE+0.420
- DNA_REPAIR+0.400
Top 10 suppressed
- TGF_BETA_SIGNALING-0.550
- ANGIOGENESIS-0.510
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.490
- UV_RESPONSE_DN-0.480
- PROTEIN_SECRETION-0.460
- HEDGEHOG_SIGNALING-0.430
- ESTROGEN_RESPONSE_EARLY-0.350
- KRAS_SIGNALING_UP-0.300
- COAGULATION-0.270
- APICAL_JUNCTION-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-D8-A1Y3-01A-11R-A157-07 | — | B | 0.918 |
| 2 | TCGA-E2-A14R-01A-11R-A115-07 | — | E | 0.888 |
| 3 | 992ce1bc-46a2-4f57-ac7a-c6368c69c67c | — | — | 0.887 |
| 4 | TCGA-D8-A1XL-01A-11R-A14M-07 | — | B | 0.884 |
| 5 | MBCProject_5971_T2_RNA | — | C | 0.881 |
| 6 | TCGA-66-2758-01A-02R-0851-07 | — | cohortSQ2 | 0.871 |
| 7 | TCGA-A2-A3Y0-01A-11R-A239-07 | — | E | 0.870 |
| 8 | SRR6013558 | — | cohortA4 | 0.869 |
| 9 | ERR2278852 | — | — | 0.869 |
| 10 | SRR8518323 | — | E | 0.867 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.680 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.590 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.580 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.540 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.480 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.460 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.460 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.430 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.420 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.330 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.260 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.240 | Remibrutinib | — uncovered |
| PEROXISOME | 0.180 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.160 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.140 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.140 | Remibrutinib | — uncovered |